Table 3.

Description of Patients With/Without hsTnI Elevation After ICI Administration

	hsTnI Elevation (+) (n = 18)	hsTnI Elevation (–) (n = 111)	P Value
Age, y	67.3 ± 15.5	65.4 ± 10.4	0.50
Male	15 (83.3)	83 (74.8)	0.56
Hypertension	6 (33.3)	35 (31.5)	>0.99
Diabetes mellitus	0 (0.0)	14 (12.6)	0.22
Dyslipidemia	1 (5.6)	15 (13.5)	0.47
Chronic kidney disease	8 (44.4)	32 (28.8)	0.27
Current or prior smoking	12 (66.7)	67 (60.4)	0.80
Baseline
BNP, pg/mL	22.0 (10.3-40.0)	20.1 (10.1-34.1)	0.88
Elevated TnI	1 (5.6)	2 (1.8)	0.38
GLS, %	17.3 (16.7-18.5)	17.7 (16.2-19.3)	0.69
Basal LS, %	16.0 (13.2-17.5)	15.8 (14.3-17.9)	0.65
Mid LS, %	18.3 (16.2-19.7)	18.0 (16.3-19.7)	0.96
Apical LS, %	20.4 (18.7-22.7)	20.0 (18.3-22.3)	0.77
LVEF, %	65.2 (62.2-66.7)	65.0 (62.5-67.8)	0.73
Days 8-14 after ICI
GLS
Absolute value, %	15.7 (14.8-17.4)	17.7 (16.3-18.7)	0.005
Relative change ≥15%	4 (22.2)	5 (4.5)	0.022
Relative change ≥12.5%	5 (27.8)	14 (12.6)	0.14
Relative change ≥10%	7 (38.9)	21 (18.9)	0.069
Basal LS
Absolute value, %	14.6 (13.5-15.6)	15.8 (13.8-17.3)	0.026
Relative change ≥15%	5 (27.8)	17 (15.3)	0.19
Relative change ≥12.5%	8 (44.4)	21 (18.9)	0.029
Relative change ≥10%	10 (55.6)	28 (25.2)	0.013
Mid LS
Absolute value, %	16.2 (15.1-18.1)	17.8 (16.5-19.0)	0.023
Relative change ≥15%	4 (22.2)	12 (10.8)	0.24
Relative change ≥12.5%	5 (27.8)	15 (13.5)	0.16
Relative change ≥10%	8 (44.4)	21 (18.9)	0.029
Apical LS
Absolute value, %	18.5 (16.3-21.3)	20.0 (17.9-21.9)	0.14
Relative change ≥15%	4 (22.2)	20 (18.0)	0.74
Relative change ≥12.5%	5 (27.8)	28 (25.2)	0.78
Relative change ≥10%	6 (33.3)	34 (30.6)	0.79
LVEF, %	64.9 (62.1-67.3)	65.1 (62.6-66.7)	0.98

Values are mean ± SD, n (%), or median (IQR).

LS = longitudinal strain; other abbreviations as in Table 1.